Important Deadlines for Ottawa NMD 2023
The Ottawa International Conference on Neuromuscular Disease and Biology (Ottawa NMD 2023) deadline for discounted early-bird registration and abstract submission is June 30th!
The Ottawa NMD 2023 Conference will feature top international basic and clinical neuromuscular (NMD) researchers highlighting advances in neuromuscular disease research and clinical care, including novel diagnostic techniques, disease pathogenesis, basic muscle and stem cell biology, and promising therapies to treat these devastating disorders. Sessions will be organized to include basic, translational and clinical presentations to engage all attendees, regardless of background or training. New for this year are more clinical sessions and Continuing Medical Education (CME) credits!
Please visit the Ottawa NMD 2023 website for the latest information about the conference including updates to the confirmed speaker list.
NMD4C Annual Meeting to Take Place Directly Before Ottawa NMD 2023
The NMD4C Annual Meeting will take place in Ottawa during the day on Thursday September 7th before Ottawa NMD 2023 begins. The NMD4C meeting will be an opportunity to share your input on the network’s future activities, discuss emerging topics in NMDs, recognize NMD4C early-career awardees and funding recipients, and network with Canadian neuromuscular clinicians and researchers. Don’t miss this opportunity to attend both events! More information on the NMD4C Annual Meeting is available here.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.